Form 4: Arcus Biosciences CMO Sells Shares for Tax Obligations

Arcus Biosciences' Chief Medical Officer, Richard Markus, sold shares to cover tax withholding obligations related to RSU vesting, not as a discretionary trade.

Summary

• Richard Markus, Chief Medical Officer of Arcus Biosciences, Inc. (RCUS), reported two non-discretionary sales of common stock.
• On December 16, 2025, 5,052 shares were sold at a weighted average price of $21.8843 per share, with prices ranging from $21.42 to $22.39.
• On December 17, 2025, an additional 4,494 shares were sold at a weighted average price of $22.1595 per share, with prices ranging from $21.92 to $22.42.
• These sales were executed automatically by the issuer on Mr. Markus's behalf to cover tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs).
• The sales were conducted pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and do not represent discretionary trades by Mr. Markus.
• Following these transactions, Mr. Markus beneficially owns 65,647 shares of common stock, which includes the unvested portion of his RSU grants.
• A correction was noted regarding the vesting schedule for equity awards granted on February 10, 2025: RSUs vest in four equal annual installments beginning December 15, 2025, and options become exercisable in 48 equal monthly installments after January 31, 2025, both subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold, the transactions were non-discretionary and for tax purposes, not indicative of a lack of confidence. The correction of the vesting schedule provides clarity.

Positives

• The share sales were non-discretionary, executed automatically to cover tax obligations, indicating they were not a reflection of a change in management's confidence in the company.
• The vesting of RSUs and exercisability of options are contingent on the reporting person's continued service, aligning executive incentives with long-term company performance.

Negatives

• The transactions resulted in a reduction of the Chief Medical Officer's direct beneficial ownership by a total of 9,546 shares.

Future Outlook

The filing clarifies the future vesting schedule for equity awards granted on February 10, 2025, with RSUs vesting annually starting December 15, 2025, and options becoming exercisable monthly after January 31, 2025, contingent on continued service.

Management Comments

• The sales occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and do not represent a discretionary trade by the reporting person.

Industry Context

Form 4 filings are standard disclosures for insider transactions, providing transparency into changes in beneficial ownership by company officers, directors, and significant shareholders. Tax-related sales of equity compensation are common and generally not indicative of a change in company fundamentals or insider sentiment.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor reduction in insider ownership, but the non-discretionary nature of the sales mitigates concerns about management's confidence.
• Employees (specifically the reporting person): Clarification of equity award vesting schedules provides certainty regarding future compensation.

Next Steps

• Continued vesting of RSUs in four equal annual installments beginning December 15, 2025.
• Continued exercisability of options in 48 equal monthly installments after January 31, 2025.

Key Dates

Recommendation

This Form 4 details routine, non-discretionary share sales by a Chief Medical Officer to cover tax obligations arising from RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment thesis.

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Stock Sale, RSU, Equity Compensation, Tax Withholding, Chief Medical Officer, Vesting Schedule